Run3D
Offering the most accurate assessment of running biomechanics that modern science is able to provide.
Incorporated in December 2012
Origin: Oxford University, Department of Engineering Science
Companies formed
Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
Salience Labs
Methods and systems for performing multiplication operations in waveguides using photonic switching elements.
Incorporated in February 2021
Origin: Oxford University, Department of Materials
Salunda (Oxford RF Sensors)
Robust, networked sensors for oilfield machinery, drilling and metering.
Incorporated in June 2005
Origin: Oxford University, Department of Chemistry
Sandymount
Development and characterisation of novel, first-in-class, selective and potential small molecule inhibitors targeting the YEATS Domain (YD) of MLLT1 and MLLT3.
Incorporated in August 2021
Origin: Oxford University, NDM, RDM, NDORMS
Scenic Biotech BV
Exploitation of proprietary ‘Cell seq’ Technology platform
Incorporated in March 2017
Origin: Oxford University, Ludwig Institute
Seloxium
Help customers obtain high-purity metals from their waste or process streams in a simple & highly profitable manor and achieve sustainability goals by removing toxic metals from wastewater.
Incorporated in September 2022
Origin: Oxford University, Engineering
Semmle
SemmleCode is a line of products aimed to help developer teams improve their software quality.
Incorporated in March 2008
Origin: Oxford University, Department of Computer Science
Sense Proteomics Ltd (acquired by Oxford Gene Technology)
Pharmaceutical services. In 2009 Sense Proteomics Ltd was acquired by Oxford Gene Technology (OGT).
Incorporated in November 1998
Origin: Oxford University
SerenOx
Aim to deliver rapid diagnosis of inherited blood disorders, infectious diseases and early-stage cancer in sub-Saharan Africa.
Incorporated in October 2022
Origin: Oxford University, Oncology
Singula Bio
Method for ranking/selecting mitochondrial neoantigens for targeted cell therapy.
Incorporated in November 2020
Origin: Oxford University, Nuffield Dept of Women's and Reproductive Health
Skylark Works
Harness connections, promote collaboration and deliver practical projects for social impact.
Incorporated in November 2020
Origin: Oxford University, Department of Education
SnowFox Discovery
Aims to identify and explore natural hydrogen sources.
Incorporated in July 2023
Origin: Oxford University, Earth Sciences
Sonosine (Oxford Enhanced Medical Limited)
Their system uses electromagnetic and acoustic waves to create a new class of medical images at a cost comparable to ultrasound.
Incorporated in October 2015
Origin: Oxford University, Department of Engineering Science
sOPHIa Oxford
A not for profit company providing a solution and accreditation to businesses that work to bring their workforce out of multidimensional poverty
Incorporated in November 2018
Origin: Oxford University, International Development
Spintex Engineering
To develop commercially scalable manufacturing process for spinning spider silk.
Incorporated in January 2020
Origin: Oxford University, Department of Zoology
Contact: Adam Workman
SpyBiotech
Pioneering a powerful new approach to generate vaccines.
Incorporated in March 2017
Origin: Oxford University, Department of Biochemistry
SugaROx
Crop biostimulants for global food security
Incorporated in March 2018
Origin: Oxford University, Department of Chemistry
Summit plc
Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.
Incorporated in February 2003
Origin: Oxford University, Department of Biochemistry
Summit Therapeutics
Chemical genomics.
Incorporated in February 2003
Origin: Oxford University
Surface Therapeutics (acquired by Serentis)
Surface Therapeutics is a drug discovery and development company developing innovative new drugs to treat inflammatory epithelial diseases of the skin and lungs. Surface Therapeutics was acquired by Serentis Inc in September 2007.
Incorporated in November 2004
Origin: Oxford University, Wellcome Trust Centre for Human Genetics
© Oxford University Innovation